Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05523596 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

A Phase 1 study of Safety Issues, sponsored by IC-MedTech Corporation.

Active
Registry status
Phase 1
Development phase
13
Enrollment target
3
Study locations

NCT05523596 is a Phase 1 study of Safety Issues that is active but no longer recruiting, run by IC-MedTech Corporation. The registered enrollment target is 13 participants, below the 119-participant average among 13 other Safety Issues trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05523596, a Phase 1 study of Safety Issues, is active but no longer recruiting, sponsored by IC-MedTech Corporation.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
13 participants
Enrollment target
3
Study locations

Study Summary

A Phase 1 Non-Randomized Open Label Study of Oral ICM20

Conditions Studied

Interventions

  • DRUG Benznidazole
  • DRUG ICM20

Study Locations (3)

Maryland

  • Parkway Medical - Glen Burnie

Texas

  • Baylor College of Medicine - Houston

Virginia

  • Culmore Clinic - Falls Church

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2022-12-20
Est. Completion 2027-03
Phase Phase 1

Sponsor

IC-MedTech Corporation

2 total trials

What the Registry Record Tells You About NCT05523596

The ClinicalTrials.gov registry entry for NCT05523596 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 13 other Safety Issues trials with a reported enrollment target (89% lower). The listed sponsor is IC-MedTech Corporation, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Safety Issues appearing as the primary indexed condition, and to 2 interventions - of which Benznidazole is the first listed.

NCT05523596 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Texas, Virginia.

Frequently Asked Questions

What is clinical trial NCT05523596 about?

NCT05523596 is a clinical study titled "A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults". A Phase 1 Non-Randomized Open Label Study of Oral ICM20

What is the current status of trial NCT05523596?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-12-20. Estimated completion is 2027-03.

What conditions does trial NCT05523596 study?

This clinical trial studies the following conditions: Safety Issues.

What interventions are being tested in trial NCT05523596?

The interventions under investigation include: Benznidazole (DRUG), ICM20 (DRUG).

Who is sponsoring clinical trial NCT05523596?

This trial is sponsored by IC-MedTech Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05523596 being conducted?

This trial has 3 study locations across Maryland, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Safety Issues

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.